Gene · 80329
ULBP1: UL16 binding protein 1
12 sourcesgene-search-2026-11-11-0.2.0
Cite this record
ConductScience Library. ULBP1: UL16 binding protein 1. Genes, record 80329. Release gene-search-2026-11-11-0.2.0, 11 Nov 2026. https://conductscience.org/library/genes/80329
On this page
Gene
Proteins1
Reviewed human proteins whose Swiss-Prot entry states the gene.
| UniProt entry | Protein | Length | Structures | Gene stated in |
|---|---|---|---|---|
| Q9BZM6 | UL16-binding protein 1 | 244 | 0 | Ensembl, GeneID, HGNC |
Source UniProt
Patents63
Patents whose sequence listing contains this protein's exact sequence. A patent can list a sequence without claiming it.
| Publication | Published | SEQ ID NO | Protein | Source |
|---|---|---|---|---|
| JP 2026004568 A | 2026-01-14 | 69268 | Q9BZM6 | Espacenet |
| JP 2026004568 A | 2026-01-14 | 69269 | Q9BZM6 | Espacenet |
| JP 2026500896 A | 2026-01-09 | 153 | Q9BZM6 | Espacenet |
| EP 4650780 A2 | 2025-11-19 | 747 | Q9BZM6 | Espacenet |
| WO 2025235604 A1 | 2025-11-13 | 153 | Q9BZM6 | Espacenet |
| WO 2025235605 A1 | 2025-11-13 | 153 | Q9BZM6 | Espacenet |
| WO 2025231174 A1 | 2025-11-06 | 25 | Q9BZM6 | Espacenet |
| EP 4641201 A2 | 2025-10-29 | 524 | Q9BZM6 | Espacenet |
| JP 2025529142 A | 2025-09-04 | 5181 | Q9BZM6 | Espacenet |
| US 12371689 B2 | 2025-07-29 | 5181 | Q9BZM6 | Espacenet |
1 to 10 of 63
See all 63 patentsDrugs0
Drugs a ChEMBL mechanism record says act on the gene's protein, through Open Targets.
None in this release.
Trials0
Trials of those drugs. A trial joins the gene only through a drug that acts on it.
None in this release.
NIH grants601
NIH grants whose papers are about the gene, through NIH's grant-paper links.
| Grant | Title | ULBP1 papers | Newest fiscal year |
|---|---|---|---|
| P30CA021765 | Cancer Center Support Grant (CCSG) | 6 | 2025 |
| P30CA016672 | Cancer Center Support Grant | 5 | 2025 |
| P30CA016056 | Roswell Park Cancer Center Support Grant | 4 | 2025 |
| R01DK088199 | Endoplasmic reticulum stress and intestinal inflammation | 4 | 2025 |
| P30AR069655 | Rochester Resource-Based Center for Bone, Muscle and Orthopaedic Research (ROCSTARR) (Overall Application) | 3 | 2025 |
| P30CA008748 | Cancer Center Support Grant | 3 | 2025 |
| P30CA093373 | Cancer Center Support Grant P30 | 3 | 2025 |
| P30DK034854 | Integrated Epithelial and Muscosal Biology | 3 | 2025 |
| R01DK044319 | Characterization of Mucosal Lymphocytes | 3 | 2025 |
| R01DK051362 | Regulation of Mucosal Lymphocytes | 3 | 2025 |
1 to 10 of 601Source NIH's project files
See all 601 nih grantsPapers1,302
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| ULBP1 is a prognostic biomarker associated with immune suppression in breast cancer. | Front Oncol | 2026 | 42718478 | PubTator, text mining | PubMed |
| KRASG12D inhibition reprograms the tumor-induced immunosuppressive environment and enhances NK cell-mediated antitumor immunity. | Sci Adv | 2026 | 42490421 | PubTator, text mining | PubMed |
| Cerebrospinal Fluid Transcriptional Immune Pathways Linked to Survival in HIV-Associated Tuberculous Meningitis. | J Infect Dis | 2026 | 42313402 | PubTator, text mining | PubMed |
| Increased ULBP1 by doxorubicin sensitizes neuroblastoma to γδT-cell cytotoxicity. | J Immunol | 2026 | 42309532 | PubTator, text mining | PubMed |
| Multi-mechanistic mitochondria-mediated N-methylated YKWYYRGAA-decorated nano-chitosan conjugate carrier for treatment of NRAS-mutant-harbouring lung carcinoma. | Carbohydr Polym | 2026 | 42230031 | PubTator, text mining | PubMed |
| Xylooligosaccharides ameliorate intestinal barrier injury by inhibiting apoptosis, RhoA/ROCK/MLCK signaling and NKG2DLs in intestinal epithelial cells. | Food Res Int | 2026 | 42116516 | PubTator, text mining | PubMed |
| Unraveling the implications of ULBP1 expression from pan-cancer to head and neck squamous cell carcinoma. | Sci Rep | 2026 | 42106428 | PubTator, text mining | PubMed |
| Metformin drives HIF-1α-mediated dual metabolic reprogramming to enhance γδ T cell therapy in triple-negative breast cancer. | Cancer Immunol Immunother | 2026 | 41925872 | PubTator, text mining | PubMed |
| Emerging immune checkpoint targets and combination strategies in blood cancer immunotherapy. | Ann Hematol | 2026 | 41915070 | PubTator, text mining | PubMed |
| cGAS/STING-mediated upregulation of NKG2D ligands in LSCs contributes to enhanced sensitivity to NK cells. | Front Oncol | 2026 | 41809821 | PubTator, text mining | PubMed |
1 to 10 of 1,302
See all 1,302 papersSources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this gene from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/genes/v1/80329
GET https://conductscience.org/api/genes/v1/80329/patents?page=2